Skip to content
OpenCapital
Get started

Viking Therapeutics VKTX Deposits on Licenses

Other financials

Income statement

See full
Revenue-—
Operating income-$164.1M-196%
Net income-$158.3M-247%
EPS (diluted)-$1.37-234%

Balance sheet

See full
Cash & equivalents$118.1M+211%
Total debt$137.0K-87.8%
Total equity$501.9M-40.7%
Total assets$608.2M-29.8%

Cash flow

See full
Operating cash flow-$114.0M-118%

Valuation

See full
Market cap$4.04B+38.7%

Returns & leverage

See full
Return on equity-70%-94.5pp
Debt / equity0×0.0×
Current ratio5.7×-38.5×

Where this comes from

Reported directly by Viking Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:DepositsAssetsNoncurrent.

The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Viking Therapeutics's deposits on licenses?
Viking Therapeutics (VKTX) reported deposits on licenses of $33K in Q1 2026.
How has Viking Therapeutics's deposits on licenses changed year-over-year?
Viking Therapeutics's deposits on licenses decreased by 28.3% year-over-year, from $46K to $33K.
What is the long-term trend for Viking Therapeutics's deposits on licenses?
Over 5 years (2020 to 2025), Viking Therapeutics's deposits on licenses has grown at a 9.7% compound annual growth rate (CAGR), from $29K to $46K.